The safety of lurbinectedin, a chemotherapeutic agent used to treat various cancers, is closely monitored by regulatory agencies and pharmaceutical companies. According to the United States Food and Drug Administration (FDA) [1], lurbinectedin was approved in 2019 under the accelerated approval program, and as a condition of approval, the manufacturer, Servier, is required to conduct ongoing safety monitoring and post-marketing studies.

One of the post-marketing studies, the Lurbinectedin Long-Term Follow-up in Relapsed or Refractory Small Cell Lung Cancer Patients (LURIC-303) trial, is listed on the ClinicalTrials.gov registry [2]. This study aims to further assess the long-term safety and efficacy of lurbinectedin in patients with relapsed or refractory small cell lung cancer.

Additionally, the manufacturer, Servier, has a patient safety program in place, which includes monitoring for adverse events, reviewing and assessing safety data, and submitting safety reports to regulatory agencies as required [3].

For up-to-date information on lurbinectedin's ongoing safety monitoring efforts, the FDA, Servier, and ClinicalTrials.gov are valuable resources.

References:

[1] United States Food and Drug Administration. (2019). Lurbinectedin. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212111s000lbl.pdf

[2] ClinicalTrials.gov. (n.d.). Lurbinectedin Long-Term Follow-up in Relapsed or Refractory Small Cell Lung Cancer Patients (LURIC-303). Retrieved from https://clinicaltrials.gov/ct2/show/NCT04077441

[3] Servier. (n.d.). Lurbinectedin Patient Safety Program. Retrieved from https://www.lurbinostat.com/patient-safety-program/

DrugPatentWatch.com provides a valuable resource for tracking the patent status and regulatory approvals of lurbinectedin.